[HTML][HTML] Repositionnement de la chlorpromazine dans le traitement du COVID-19: étude reCoVery
Résumé Objectifs La pandémie mondiale actuelle de COVID-19 a touché environ 2 350 000
personnes et fait plus de 160 000 morts. Nous avons observé dans le GHU de Paris …
personnes et fait plus de 160 000 morts. Nous avons observé dans le GHU de Paris …
The validation path of hypoxia PET imaging: focus on brain tumours
N Quartuccio, MC Asselin - Current Medicinal Chemistry, 2018 - ingentaconnect.com
Background: Gliomas are brain tumours arising from the glia, the supportive tissue of the
central nervous system (CNS), and constitute the commonest primary malignant brain …
central nervous system (CNS), and constitute the commonest primary malignant brain …
[HTML][HTML] Novel dopamine receptor 3 antagonists inhibit the growth of primary and temozolomide resistant glioblastoma cells
SE Williford, CJ Libby, A Ayokanmbi, A Otamias… - PloS one, 2021 - journals.plos.org
Treatment for the lethal primary adult brain tumor glioblastoma (GBM) includes the
chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with …
chemotherapy temozolomide (TMZ), but TMZ resistance is common and correlates with …
Design, Synthesis, Anticancer and Antimicrobial Studies of 2‐Phenylthiazolidin‐4‐one Glycinamide Conjugates
Thiazolidin‐4‐one is a versatile nucleus that has been reported to exhibit a diverse array of
biological activities, including anticancer and antimicrobial activities. In the current research …
biological activities, including anticancer and antimicrobial activities. In the current research …
[HTML][HTML] Propranolol inhibits the proliferation of human glioblastoma cell lines through notch1 and hes1 signaling system
HS Kim, YH Park, HS Lee, MJ Kwon… - Journal of Korean …, 2021 - synapse.koreamed.org
Objective The anti-tumor effect of the beta-adrenergic receptor antagonist propranolol in
breast cancer is well known; however, its activity in glioblastoma is not well-evaluated. The …
breast cancer is well known; however, its activity in glioblastoma is not well-evaluated. The …
[HTML][HTML] Phosphatidylinositol 3-kinase/AKT pathway inhibition by doxazosin promotes glioblastoma cells death, upregulation of p53 and triggers low neurotoxicity
MM Gaelzer, BP Coelho, AH De Quadros, JB Hoppe… - PLoS …, 2016 - journals.plos.org
Glioblastoma is the most frequent and malignant brain tumor. Treatment includes
chemotherapy with temozolomide concomitant with surgical resection and/or irradiation …
chemotherapy with temozolomide concomitant with surgical resection and/or irradiation …
Antipsychotic drugs elicit cytotoxicity in glioblastoma multiforme in a calcium‐dependent, non‐D2 receptor‐dependent, manner
JS Weissenrieder, JL Reed… - Pharmacology …, 2021 - Wiley Online Library
Dopamine D2‐like receptor antagonists have been suggested as being potential anticancer
therapeutics with specific utility for central nervous system cancers due to their ability to …
therapeutics with specific utility for central nervous system cancers due to their ability to …
[HTML][HTML] Blood–brain barrier crossing and breakthroughs in glioblastoma therapy
P Sminia, BA Westerman - British journal of clinical pharmacology, 2016 - ncbi.nlm.nih.gov
Glioblastoma is a heterogeneous tumour type which is highly resistant to radiotherapy and
chemotherapy. Clinical results following standard therapy as well as new approaches using …
chemotherapy. Clinical results following standard therapy as well as new approaches using …
[HTML][HTML] Virtual screening and drug repositioning as strategies for the discovery of new antifungal inhibitors of oxidosqualene cyclase
VWH Rabelo, D de Jesus Viegas, EMN Tucci… - The Journal of Steroid …, 2019 - Elsevier
Candidiasis is the most common fungal infection in immunocompromised patients, and
Candida albicans is the fourth leading agent of nosocomial infections. Mortality from this …
Candida albicans is the fourth leading agent of nosocomial infections. Mortality from this …
Repurposed drugs in treating glioblastoma multiforme: Clinical trials update
Glioblastoma (GBM) is the most common and lethal primary malignant brain tumors in adults
with distinct molecular features and has a median survival of less than 15 months, and 5 …
with distinct molecular features and has a median survival of less than 15 months, and 5 …